Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday.
Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what’s expected to be a 230-patient, Phase III study.
In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including heart failure.
Help employers find you! Check out all the jobs and post your resume.
